Login to Your Account

In The Clinic NEWS

PERTH, Australia – Australian cell therapy developer Mesoblast Ltd. is moving to phase III trials with its allogeneic mesenchymal precursor cell therapy to treat chronic low back pain due to intervertebral disc degeneration.

Adding the investigational advanced breast cancer candidate, abemaciclib, to the already-approved drug fulvestrant, reduced the risk of disease worsening or death for women with hormone-receptor-positive, HER2-negative disease more than adding a placebo, Eli Lilly and Co. reported.

LONDON – Ergomed plc has started the phase IIb trial of Peprostat, the first synthetic peptide hemostat, which it said will offer faster clotting while removing concerns around plasma-derived thrombin products.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: